The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
The effect of tepotinib on c-MET, β-catenin, ERK, and c-MYC protein... | Download Scientific Diagram
Cancers | Free Full-Text | Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
PDF) SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
Molecular and Clinical Profile of Patients with NSCLC with METex14... | Download Scientific Diagram
Tepotinib granted FDA priority review for METex14 NSCLC | BLU Ampersand, Inc.
New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib | Merck
Cancers | Free Full-Text | Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Tepotinib clinical trials: Investigating MET inhibition in NSCLC and mCRC
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Newly approved therapies for METex14 and METamp lung cancers
MET Inhibitors Active in Advanced NSCLC | MedPage Today
A study to learn about the effects and safety of tepotinib plus osimertinib in patients with MET-amplified non-small cell lung c
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management - ScienceDirect
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
EMD SERONO | MET PATHWAY
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | British Journal of Cancer
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect
Tepotinib Demonstrates Durable Benefit With High-Level MET Amplification
Now Enrolling: VISION Clinical Trial: Advanced/Metastatic NSCLC With MET Alterations
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation | Journal of Hematology & Oncology | Full Text
![PDF] The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e3a026eea26e4f2336369569f57302b519c3abf6/3-Figure1-1.png "PDF] The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. | Semantic Scholar")